scholarly journals A Novel RNA-Binding Protein-Based Nomogram for Predicting Survival of Patients with Gastric Cancer

2020 ◽  
Vol 27 ◽  
Author(s):  
Maoshu Zhu ◽  
Jiading Cai ◽  
Yulong Wu ◽  
Xinhong Wu ◽  
Lianghua Feng ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Rna Binding ◽  
Binding Protein ◽  
Rna Binding Protein

scholarly journals RNA-binding protein RNPC1 acts as an oncogene in gastric cancer by stabilizing Aurora kinase B mRNA

2021 ◽  
pp. 112741
Author(s):  
Chun-Mei Ji ◽  
Xu Zhang ◽  
Wentong Fang ◽  
Ling Meng ◽  
Xiaolong Wei ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Rna Binding ◽  
Binding Protein ◽  
Rna Binding Protein ◽  
Aurora Kinase ◽  
Aurora Kinase B

scholarly journals Development and validation of RNA binding protein-applied prediction model for gastric cancer

Aging ◽  
2021 ◽  
Vol 13 (4) ◽  
pp. 5539-5552
Author(s):  
Shuang Dai ◽  
Yan Huang ◽  
Ting Liu ◽  
Zi-Han Xu ◽  
Tao Liu ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Prediction Model ◽  
Rna Binding ◽  
Binding Protein ◽  
Rna Binding Protein ◽  
Development And Validation

scholarly journals The Aberrant Expression of MicroRNA-125a-5p/IGF2BP3 Axis in Advanced Gastric Cancer and Its Clinical Relevance

2020 ◽  
Vol 19 ◽  
pp. 153303382091733
Author(s):  
Jing Zhang ◽  
Fanghui Ding ◽  
Dan Jiao ◽  
Qiaozhi Li ◽  
Hong Ma
Keyword(s):  
Gastric Cancer ◽  
Growth Factor ◽  
Advanced Gastric Cancer ◽  
Messenger Rna ◽  
Poor Prognosis ◽  
Rna Binding ◽  
Binding Protein ◽  
Rna Binding Protein ◽  
Advanced Stage ◽  
Insulin Like Growth Factor

RNA-binding proteins have been associated with cancer development. The overexpression of a well-known RNA-binding protein, insulin-like growth factor 2 messenger RNA–binding protein 3, has been identified as an indicator of poor prognosis in patients with various types of cancer. Although gastric cancer is a relatively frequent and potentially fatal malignancy, the mechanism by which insulin-like growth factor 2 messenger RNA–binding protein 3 regulates the development of this cancer remains unclear. This study aimed to investigate the role and regulatory mechanism of insulin-like growth factor 2 messenger RNA–binding protein 3 in gastric cancer. An analysis of IGF2BP3 expression patterns reported in 4 public gastric cancer–related microarray data sets from the Gene Expression Omnibus and The Cancer Genome Atlas-Stomach Adenocarcinoma revealed strong expression of this gene in gastric cancer tissues. Insulin-like growth factor 2 messenger RNA–binding protein 3 expression in gastric cancer was further confirmed via quantitative reverse transcription polymerase chain reaction and immunohistochemistry, respectively, in an in-house gastric cancer cohort (n = 30), and the association of insulin-like growth factor 2 messenger RNA–binding protein 3 expression with clinical parameters and prognosis was analyzed. Notably, stronger IGF2BP3 expression significantly correlated with poor prognosis, and significant changes in insulin-like growth factor 2 messenger RNA–binding protein 3 expression were only confirmed in patients with advanced-stage gastric cancer in an independent cohort. The effects of insulin-like growth factor 2 messenger RNA–binding protein 3 on cell proliferation were confirmed through in vitro experiments involving the HGC-27 gastric cancer cell line. MicroR-125a-5p, a candidate microRNA that target on insulin-like growth factor 2 messenger RNA–binding protein 3, decreased in advanced-stage gastric cancer. Upregulation of microR-125a-5p inhibited insulin-like growth factor 2 messenger RNA–binding protein 3, and dual-luciferase report assay indicated that microR-125a-5p inhibited the translation of IGF2BP3 by directly targeting the 3′ untranslated region. These results indicate that the microR-125a-5p/insulin-like growth factor 2 messenger RNA–binding protein 3 axis contributes to the oncogenesis of advanced gastric cancer.

Abstract 5162: Id1 is an oncogenic target of RNA binding protein HuR in gastric cancer

2016 ◽  
Author(s):  
Shuang Han ◽  
Xiaoqing Wu ◽  
Yuxiao Guo ◽  
Jing Zhang ◽  
Xuan Gu ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Rna Binding ◽  
Binding Protein ◽  
Rna Binding Protein

scholarly journals A Novel RNA-Binding Protein Signature to Predict Clinical Outcomes and Guide Clinical Therapy in Gastric Cancer

2021 ◽  
Vol 8 ◽  
Author(s):  
Zhigang Qiu ◽  
Haitao Jiang ◽  
Kun Ju ◽  
Xichun Liu
Keyword(s):  
Gastric Cancer ◽  
High Risk ◽  
Clinical Outcomes ◽  
Rna Binding ◽  
Binding Protein ◽  
Rna Binding Protein ◽  
Low Risk ◽  
Survival Prediction ◽  
Clinical Therapy ◽  
Tumor Purity

Objective: This study aimed to develop an RNA-binding protein (RBP)-based signature for risk stratification and guiding clinical therapy in gastric cancer.Methods: Based on survival-related RBPs, an RBP-based signature was established by LASSO regression analysis in TCGA dataset. Kaplan–Meier curves were drawn between high- and low-risk groups. The predictive efficacy of this signature was assessed via ROCs at 1-, 3-, and 5-year survival. Its generalizability was verified in an external dataset. Following adjustment with other clinicopathological characteristics, the independency of survival prediction was evaluated via multivariate Cox regression and subgroup analyses. GSEA was utilized in identifying activated pathways in two groups. Stromal score, immune score, tumor purity, and infiltration levels of 22 immune cells were determined in each sample via the ESTIMATE and CIBERSORT algorithms. The sensitivity to chemotherapy drugs was assessed through the GDSC database.Results: Data showed that patients with high risk exhibited unfavorable clinical outcomes than those with low risk. This signature possessed good performance in predicting 1-, 3-, and 5-year survival and can be independently predictive of patients' survival. Calcium, ECM receptor interaction, and focal adhesion were highly enriched in high-risk samples. High-risk samples presented increased stromal and immune scores and reduced tumor purity. Moreover, this signature presented close relationships with immune infiltrations. Low-risk specimens were more sensitive to sorafenib, gefitinib, vinorelbine, and gemcitabine than high-risk specimens.Conclusion: This RBP-based signature may be a promising tool for predicting clinical outcomes and guiding clinical therapy in gastric cancer.

235: The RNA-Binding Protein IMP3: A Novel Molecular Marker Predicts Progression of Superficial (TA and T1) Urothelial Carcinomas of Bladder

2007 ◽  
Vol 177 (4S) ◽  
pp. 78-79
Author(s):  
Lioudmila Sitnikova ◽  
Gary Mendese ◽  
Qin Lui ◽  
Bruce A. Woda ◽  
Di Lu ◽  
...  
Keyword(s):  
Molecular Marker ◽  
Rna Binding ◽  
Binding Protein ◽  
Rna Binding Protein ◽  
Urothelial Carcinomas
Sign in / Sign up

Export Citation Format

Share Document